OCUP - Ocuphire shares surge on positive Nyxol data in reversal of mydriasis

Ocuphire Pharma (OCUP) jumps 37% premarket after announcing positive top line results in the MIRA-2 Phase 3 registration trial investigating Nyxol for reversal of pharmacologically induced mydriasis (dilation of pupil for eye exams).MIRA-2 trial met its primary endpoint with 49% of subjects treated with Nyxol returning to ? 0.2 mm of their baseline pupil diameter at 90 minutes compared to 7% of subjects treated with placebo (p <0.0001).Nyxol showed a statistically significant improvement on multiple secondary endpoints as well, demonstrating its ability to more rapidly return pupil diameter back to normal baselines over multiple timepoints, breadth of iris colors, and dilating agents.Nyxol treated subjects had mean pupil diameters that were 1 to 2.5 mm smaller than placebo treated subjects at all timepoints from 1 to 6 hours post-dosing.Nyxol was well-tolerated with no serious adverse events or withdrawals and demonstrated a favorable safety profile. Building on positive results, the company plans to initiate

For further details see:

Ocuphire shares surge on positive Nyxol data in reversal of mydriasis